Testing whether people with BRAF V600 low-grade glioma can stop or slowly lower dabrafenib and trametinib
Original title: Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage trial, so the drugs are still being tested in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial looks at what happens when people who have been taking two targeted drugs stop them or slowly cut the dose back.
Who this trial is for. This trial is for people with a low-grade glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary that has a BRAF V600 gene change, and who have already taken dabrafenib and trametinib for 12-24 months. It tests two ways of coming off the drugs. One is stopping both drugs completely. The other is slowly lowering the dose for an additional 6 months.
Where it stands. The trial has not reported results. It is trying to work out the best dosing plan for people who have been on these two drugs for 12-24 months. The answer is not in yet.
What this means, and what it doesn't
What it could mean: Dabrafenib and trametinib block signals that tell tumor cells to multiply. This trial is asking how long people need to keep taking them. If you fit this picture, you can ask your care team whether a trial like this makes sense for you.
What it doesn't mean: This does not mean the drugs are proven to work better one way or the other. A trial is a test, not a proven treatment. Being in a trial is not a guarantee that you will be helped. It is not a promise of a cure.
Source: ClinicalTrials.gov, August 3, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.